~~<i id='70BDFD2336'><strike id='70BDFD2336'><tt id='70BDFD2336'><pre id='70BDFD2336'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：leisure time 2025-10-01 22:04:48 Page View：627

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Better Therapeutics data on benefit with GLP
Next article： Medical leaders decry Supreme Court decision on affirmative action

leisure time

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

A revolution in caring for preterm infants

ISSOUFSANOGO/AFPviaGettyImagesMorethanonein10infantsworldwidearebornpreterm,manywithcomplications:Ne

Medicare proposal to cover medical devices draws a mixed reaction

AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

0:42ARussianfighterfliesdangerouslyclosetoaU.S.MQ-9beforedeployingflaresfromapositiondirectlyoveranM